Comparative Pharmacology
Head-to-head clinical analysis: ABREVA versus FAMCICLOVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABREVA versus FAMCICLOVIR.
ABREVA vs FAMCICLOVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits viral DNA polymerase and DNA synthesis of herpes simplex virus (HSV-1 and HSV-2).
Famciclovir is a prodrug of penciclovir, which inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate, thus inhibiting viral DNA replication. It has activity against herpes simplex virus (HSV-1, HSV-2), varicella-zoster virus (VZV), and Epstein-Barr virus (EBV).
Apply a thin layer to the affected area 5 times daily for 4 days.
500 mg orally three times daily for 7 days for herpes zoster; 125 mg twice daily for 5 days for recurrent genital herpes; 250 mg three times daily for 7 days for first-episode genital herpes; 500 mg twice daily for 7 days for recurrent herpes labialis.
None Documented
None Documented
Clinical Note
moderateFamciclovir + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Famciclovir."
Clinical Note
moderateFamciclovir + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Famciclovir."
Clinical Note
moderateFamciclovir + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Famciclovir."
Clinical Note
moderateFamciclovir + Fluconazole
Due to minimal systemic absorption, an elimination half-life cannot be accurately determined in humans. Following intravenous administration in animals, the terminal half-life is approximately 10 hours, but this is not clinically relevant for topical use.
Terminal half-life of penciclovir is 2-3 hours in healthy adults, prolonged to 3-6 hours in hepatic impairment and >20 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Docosanol is minimally absorbed after topical application; systemic absorption is negligible. Any absorbed drug is primarily metabolized and excreted via bile and feces. Renal excretion is insignificant. Less than 1% of the applied dose enters systemic circulation, and nearly all elimination occurs via biliary/fecal routes.
Renal elimination: ~60% as penciclovir (active metabolite) and <10% as unchanged famciclovir; biliary/fecal: <5%; the remainder is metabolized to inactive compounds.
Category C
Category A/B
Antiviral
Antiviral
"The metabolism of Fluconazole can be decreased when combined with Famciclovir."